Radioimmunotherapy of prostate carcinoma
© 2013 Springer Science+Business Media New York. All rights reserved.Prostate cancer accounts for 25 % of the newly diagnosed cancers among men in developed countries. With the availability of serum Prostate Specific Antigen (PSA) determinations, many patients present early with limited disease but a significant percent will experience recurrences and will eventually die from disseminated disease. Initial evaluation of the extent of disease is rendered difficult by the biology of the disease involving micrometastases in bone marrow and lymph nodes that are often too small to detect in the early stages of the disease with currently available methods. Even when a rising PSA suggests that there is residual disease, the multifocal nature of metastatic prostate carcinoma renders surgical and external beam radiation therapy of little value after treatment of the primary tumor. Whereas androgen deprivation is transiently effective as therapy for as long as 12-18 months in some patients, it is not curative. Subsequent use of chemotherapy is transiently beneficial in a subset of patients but progression of disease is inevitable. Hence, prostate carcinoma represents a distinct challenge and opportunity for radioimmunotherapy based upon selective targeting of tumor sites by an immunoglobulin to which a radioactive atom has been attached, thus serving as a vehicle for targeted radiotherapy.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency